New anticoagulant gets mixed resultsBMJ 2007; 335 doi: https://doi.org/10.1136/bmj.335.7620.586 (Published 20 September 2007) Cite this as: BMJ 2007;335:586
Idraparinux is a new anticoagulant that inhibits activated factor X. It has a long half life and can be given just once a week, by subcutaneous injection. But is it as good as standard anticoagulants at preventing recurrent venous thromboembolism⇑? …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial